» Articles » PMID: 24118188

Management and Diagnostic Guidelines for Fungal Diseases in Infectious Diseases and Clinical Microbiology: Critical Appraisal

Overview
Publisher Elsevier
Date 2013 Oct 15
PMID 24118188
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Invasive fungal infections (IFIs) are life-threatening conditions that require rapid diagnostic and optimal management to mitigate their high morbidity and mortality rate. They are also associated with a high economic burden, owing to prolonged hospitalization, the need for intensive supportive care, and the consumption of costly new antifungal agents. To address these issues, several international organizations have proposed guidelines for the management of IFIs. The consistency and reliability of these guidelines have rarely been assessed. This article is a review of the differences between the recommendations of the Infectious Diseases Society of America, the European Conference on Infection in Leukaemia, and the European Society of Clinical Microbiology and Infectious Diseases, and will focus on targeted treatment and diagnostic procedures. Although the conclusions of the three groups of experts are in many points similar we outlined some important differences in the methodology and conclusions of ESCMID. The use of these guidelines has the potential to enhance the management of fungal infections but is probably currently suboptimal.

Citing Articles

Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives.

Lian X, Scott-Thomas A, Lewis J, Bhatia M, MacPherson S, Zeng Y Int J Mol Sci. 2022; 23(10).

PMID: 35628374 PMC: 9146623. DOI: 10.3390/ijms23105563.


A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation.

Van Daele R, Bekkers B, Lindfors M, Broman L, Schauwvlieghe A, Rijnders B Microorganisms. 2021; 9(7).

PMID: 34361978 PMC: 8303158. DOI: 10.3390/microorganisms9071543.


Evaluation of Adult Outpatient Antibiotics Use at Jimma Medical Center (with Defined Daily Doses for Usage Metrics).

Melaku T, Gashaw M, Chelkeba L, Berhane M, Bekele S, Lemi G Infect Drug Resist. 2021; 14:1649-1658.

PMID: 33953576 PMC: 8092616. DOI: 10.2147/IDR.S293080.


(1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people.

White S, Schmidt R, Walker B, Hanson K Cochrane Database Syst Rev. 2020; 7:CD009833.

PMID: 32693433 PMC: 7387835. DOI: 10.1002/14651858.CD009833.pub2.


Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?.

Vena A, Munoz P, Mateos M, Guinea J, Galar A, Pea F Infect Dis Ther. 2020; 9(1):137-149.

PMID: 32026399 PMC: 7054538. DOI: 10.1007/s40121-020-00280-y.